No Data
Shed Secures Exclusive U.S. Telehealth Access to ROXUS, a Rapid-Acting Intranasal Treatment for Erectile Dysfunction Through LTR Pharma
LTR Pharma Says Interim Phase Two Data for Erectile Dysfunction Treatment Candidate Shows Rapid Time to Peak Concentration, Shares Jump 28%
Aptar's Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN Nasal Spray
LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%
LTR Pharma Lodges Half-year Appendix 4D Report With ASX
LTR Pharma Seeks ASX Quotation for Additional 50,000 Shares
MishieLee : Profit depends on the price you bought in! But hold in there, it will be a valuable stock later this year and beyond.